Literature DB >> 24667959

4-1BB chimeric antigen receptors.

Dario Campana1, Herbert Schwarz, Chihaya Imai.   

Abstract

In addition to T-cell receptor signals, T lymphocytes require costimulatory signals for robust activation. Among these, those mediated by 4-1BB (CD137, TNFRSF9) are critical for tumor immunity. 4-1BB is expressed in T-cell receptor-activated lymphocytes as well as natural killer cells and other hematopoietic and nonhematopoietic cells. 4-1BB ligation induces a signaling cascade that results in cytokine production, expression of antiapoptotic molecules, and enhanced immune responses. In line with the described function of 4-1BB, its addition to CD3ζ chimeric antigen receptors (CARs) increases their capacity to provoke T-cell expansion and antitumor activity. The results of preclinical studies with 4-1BB CARs have been corroborated by encouraging results from clinical trials. Advantages and disadvantages of 4-1BB CARs versus CARs bearing other costimulatory components remain to be fully elucidated. In this review, we discuss the properties of 4-1BB, the design of 4-1BB CARs, and the function of T lymphocytes and natural killer cells expressing them.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24667959     DOI: 10.1097/PPO.0000000000000028

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  22 in total

1.  Enterotoxins can support CAR T cells against solid tumors.

Authors:  Bianca von Scheidt; Minyu Wang; Amanda J Oliver; Jack D Chan; Metta K Jana; Aesha I Ali; Fiona Clow; John D Fraser; Kylie M Quinn; Phillip K Darcy; Michael H Kershaw; Clare Y Slaney
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-25       Impact factor: 11.205

Review 2.  A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma.

Authors:  Houli Zhao; Yiyun Wang; Elaine Tan Su Yin; Kui Zhao; Yongxian Hu; He Huang
Journal:  Front Med       Date:  2020-12-01       Impact factor: 4.592

Review 3.  CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia.

Authors:  Shannon L Maude; David T Teachey; David L Porter; Stephan A Grupp
Journal:  Blood       Date:  2015-05-21       Impact factor: 22.113

Review 4.  CD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses.

Authors:  Bhushan Dharmadhikari; Meihui Wu; Nur Sharalyn Abdullah; Sakthi Rajendran; Nur Diana Ishak; Emily Nickles; Zulkarnain Harfuddin; Herbert Schwarz
Journal:  Oncoimmunology       Date:  2015-11-11       Impact factor: 8.110

5.  Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies.

Authors:  Yi Tian Png; Natasha Vinanica; Takahiro Kamiya; Noriko Shimasaki; Elaine Coustan-Smith; Dario Campana
Journal:  Blood Adv       Date:  2017-11-21

Review 6.  Optimizing intracellular signaling domains for CAR NK cells in HIV immunotherapy: a comprehensive review.

Authors:  Giorgio Zenere; Omalla Allan Olwenyi; Siddappa N Byrareddy; Stephen E Braun
Journal:  Drug Discov Today       Date:  2019-02-13       Impact factor: 7.851

7.  A novel method to generate T-cell receptor-deficient chimeric antigen receptor T cells.

Authors:  Takahiro Kamiya; Desmond Wong; Yi Tian Png; Dario Campana
Journal:  Blood Adv       Date:  2018-03-13

Review 8.  Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice.

Authors:  Marlise R Luskin; Daniel J DeAngelo
Journal:  Curr Hematol Malig Rep       Date:  2017-08       Impact factor: 3.952

Review 9.  CAR-T Cell Therapies From the Transfusion Medicine Perspective.

Authors:  Andrew Fesnak; ChieYu Lin; Don L Siegel; Marcela V Maus
Journal:  Transfus Med Rev       Date:  2016-03-28

Review 10.  CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.

Authors:  Nathan Singh; Noelle V Frey; Stephan A Grupp; Shannon L Maude
Journal:  Curr Treat Options Oncol       Date:  2016-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.